Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer.

4 ), except for an increasing trend in OS of platinum-sensitive patients compared to platinum-resistant/refractory patients (median OS: 25.5 months vs. 13.8 months, univariate (UV) HR: 1.96, 95% CI: 1.00 to 3.85, p = 0.05) though this trend was not observed in the MV analysis (MV HR: 2.04, 95% CI: 0.83 to 4.98, p = 0.12).

also in 63,971 other papers